IBDEI0LM ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10249,1,4,0)
 ;;=4^369.08
 ;;^UTILITY(U,$J,358.3,10249,2)
 ;;=^268868
 ;;^UTILITY(U,$J,358.3,10250,0)
 ;;=369.10^^44^562^73
 ;;^UTILITY(U,$J,358.3,10250,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10250,1,3,0)
 ;;=3^One Eye-Blind,Oth-Low Vision
 ;;^UTILITY(U,$J,358.3,10250,1,4,0)
 ;;=4^369.10
 ;;^UTILITY(U,$J,358.3,10250,2)
 ;;=^268870
 ;;^UTILITY(U,$J,358.3,10251,0)
 ;;=369.11^^44^562^79
 ;;^UTILITY(U,$J,358.3,10251,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10251,1,3,0)
 ;;=3^One Eye-Severe/Oth Eye-Blind
 ;;^UTILITY(U,$J,358.3,10251,1,4,0)
 ;;=4^369.11
 ;;^UTILITY(U,$J,358.3,10251,2)
 ;;=^268871
 ;;^UTILITY(U,$J,358.3,10252,0)
 ;;=369.12^^44^562^82
 ;;^UTILITY(U,$J,358.3,10252,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10252,1,3,0)
 ;;=3^One Eye-Severe/Oth Eye-Total
 ;;^UTILITY(U,$J,358.3,10252,1,4,0)
 ;;=4^369.12
 ;;^UTILITY(U,$J,358.3,10252,2)
 ;;=^268872
 ;;^UTILITY(U,$J,358.3,10253,0)
 ;;=369.13^^44^562^80
 ;;^UTILITY(U,$J,358.3,10253,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10253,1,3,0)
 ;;=3^One Eye-Severe/Oth Eye-Near Total
 ;;^UTILITY(U,$J,358.3,10253,1,4,0)
 ;;=4^369.13
 ;;^UTILITY(U,$J,358.3,10253,2)
 ;;=^268873
 ;;^UTILITY(U,$J,358.3,10254,0)
 ;;=369.14^^44^562^81
 ;;^UTILITY(U,$J,358.3,10254,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10254,1,3,0)
 ;;=3^One Eye-Severe/Oth Eye-Profound
 ;;^UTILITY(U,$J,358.3,10254,1,4,0)
 ;;=4^369.14
 ;;^UTILITY(U,$J,358.3,10254,2)
 ;;=^268874
 ;;^UTILITY(U,$J,358.3,10255,0)
 ;;=369.22^^44^562^102
 ;;^UTILITY(U,$J,358.3,10255,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10255,1,3,0)
 ;;=3^Severe Impairment,Both Eyes
 ;;^UTILITY(U,$J,358.3,10255,1,4,0)
 ;;=4^369.22
 ;;^UTILITY(U,$J,358.3,10255,2)
 ;;=^268882
 ;;^UTILITY(U,$J,358.3,10256,0)
 ;;=369.60^^44^562^6
 ;;^UTILITY(U,$J,358.3,10256,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10256,1,3,0)
 ;;=3^Blindness,One Eye Only
 ;;^UTILITY(U,$J,358.3,10256,1,4,0)
 ;;=4^369.60
 ;;^UTILITY(U,$J,358.3,10256,2)
 ;;=^268880
 ;;^UTILITY(U,$J,358.3,10257,0)
 ;;=369.9^^44^562^115
 ;;^UTILITY(U,$J,358.3,10257,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10257,1,3,0)
 ;;=3^Visual Loss NOS
 ;;^UTILITY(U,$J,358.3,10257,1,4,0)
 ;;=4^369.9
 ;;^UTILITY(U,$J,358.3,10257,2)
 ;;=^126769
 ;;^UTILITY(U,$J,358.3,10258,0)
 ;;=377.61^^44^562^20
 ;;^UTILITY(U,$J,358.3,10258,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10258,1,3,0)
 ;;=3^D/O Pathways w/ Neoplasm
 ;;^UTILITY(U,$J,358.3,10258,1,4,0)
 ;;=4^377.61
 ;;^UTILITY(U,$J,358.3,10258,2)
 ;;=^269241
 ;;^UTILITY(U,$J,358.3,10259,0)
 ;;=379.02^^44^562^68
 ;;^UTILITY(U,$J,358.3,10259,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10259,1,3,0)
 ;;=3^Nodular Episcleritis
 ;;^UTILITY(U,$J,358.3,10259,1,4,0)
 ;;=4^379.02
 ;;^UTILITY(U,$J,358.3,10259,2)
 ;;=^269285
 ;;^UTILITY(U,$J,358.3,10260,0)
 ;;=379.07^^44^562^90
 ;;^UTILITY(U,$J,358.3,10260,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10260,1,3,0)
 ;;=3^Posterior Scleritis
 ;;^UTILITY(U,$J,358.3,10260,1,4,0)
 ;;=4^379.07
 ;;^UTILITY(U,$J,358.3,10260,2)
 ;;=^269295
 ;;^UTILITY(U,$J,358.3,10261,0)
 ;;=379.92^^44^562^106
 ;;^UTILITY(U,$J,358.3,10261,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10261,1,3,0)
 ;;=3^Swelling/Mass of Eye
 ;;^UTILITY(U,$J,358.3,10261,1,4,0)
 ;;=4^379.92
 ;;^UTILITY(U,$J,358.3,10261,2)
 ;;=^269334
 ;;^UTILITY(U,$J,358.3,10262,0)
 ;;=379.93^^44^562^94
 ;;^UTILITY(U,$J,358.3,10262,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10262,1,3,0)
 ;;=3^Redness/Discharge of Eye
 ;;^UTILITY(U,$J,358.3,10262,1,4,0)
 ;;=4^379.93
 ;;^UTILITY(U,$J,358.3,10262,2)
 ;;=^104154
 ;;^UTILITY(U,$J,358.3,10263,0)
 ;;=379.99^^44^562^86
 ;;
 ;;$END ROU IBDEI0LM
